A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies
Lillian L. Siu, Eric K. Rowinsky, Lisa A. Hammond, Geoffrey R. Weiss, Manuel Hidalgo, Gary M. Clark, Judy Moczygemba, Les Choi, Ron Linnartz, Nicholas C. Barbet, Ivo T. Sklenar, Renaud Capdeville, Gregory Gan, Carl W. Porter, Daniel D. Von Hoff, S. Gail Eckhardt
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies'. Together they form a unique fingerprint.